Table A1.

Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer Expert Panel Members

Name	Affiliation	Role/Area of Expertise
Sharon H. Giordano, MD, panel co-chair	University of Texas MD Anderson Cancer Center, Houston, TX	Medical oncology
Eric P. Winer, MD, panel co-chair	Dana-Farber Cancer Institute, Boston, MA	Medical oncology
Nancy U. Lin, MD, writing committee co-lead	Dana-Farber Cancer Institute, Boston, MA	Medical oncology
Naren Ramakrishna, MD, PhD, writing committee co-lead	University of Florida Health Cancer Center at Orlando Health, Orlando, FL	Radiation oncology
Sarat Chandarlapaty, MD, PhD	Memorial Sloan Kettering Cancer Center, New York, NY	Medical oncology
Jennie R. Crews, MD	PeaceHealth St Joseph Cancer Center, Bellingham, WA	Medical oncology, implementation
Nancy E. Davidson, MD	University of Pittsburgh Cancer Institute and UPMC Cancer Center, Pittsburgh, PA	Medical oncology
Francisco J. Esteva, MD	New York University Cancer Institute, New York, NY	Medical oncology
Ana M. Gonzalez-Angulo, MD, MSc	University of Texas MD Anderson Cancer Center, Houston, TX	Medical oncology
Jeffrey J. Kirshner, MD	Hematology/Oncology Associates of Central New York, East Syracuse, NY	Medical oncology, implementation
Ian Krop, MD, PhD	Dana-Farber Cancer Institute, Boston, MA	Medical oncology
Jennifer Levinson	Ponte Vedra Beach, FL	Advocacy
Shanu Modi, MD	Memorial Sloan Kettering Cancer Center, New York, NY	Medical oncology
Debra A. Patt, MD, MPH	Texas Oncology, Austin, TX	Medical oncology, community
Edith A. Perez, MD	Mayo Clinic, Jacksonville, FL	Medical oncology
Jane Perlmutter, PhD	Ann Arbor, MI	Biostatistics, advocacy

NOTE. American Society for Clinical Oncology staff: Sarah Temin.

Abbreviations: HER2, human epidermal growth factor receptor 2; UPMC, University of Pittsburgh Medical Center.